Filing Flows › Comparisons › GLUE vs IBRX
Monte Rosa Therapeutics vs ImmunityBio: GLUE and IBRX compared
Monte Rosa Therapeutics is the larger company: $54.4M of revenue in its latest quarter (Q3 2026) against $51.2M for ImmunityBio (Q2 2026). Monte Rosa Therapeutics is growing faster (+326% against +94% a year earlier). Monte Rosa Therapeutics is more profitable, with an operating margin of -3.6% against -120.4%.
Where the money goes: GLUE and IBRX
Monte Rosa Therapeutics (GLUE) · Q3 2026
Monte Rosa Therapeutics, Q3 2026: revenue $54.4M (+326% year over year), operating margin -3.6%, net earnings $3.1M, operating cash flow −$41.0M. The chart follows the revenue to costs, profit and cash.
ImmunityBio (IBRX) · Q2 2026
ImmunityBio, Q2 2026: revenue $51.2M (+94% year over year), operating margin -120.4%, net loss $230M, operating cash flow −$66.5M. The chart follows the revenue to costs, profit and cash.
| Monte Rosa Therapeutics (GLUE) | ImmunityBio (IBRX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $54.4M | $51.2M |
| Revenue growth, Y/Y | +326% | +94% |
| Operating margin | -3.6% | -120.4% |
| Net earnings | $3.1M | −$230M |
| Net margin | 5.6% | -449.6% |
| Operating cash flow | −$41.0M | −$66.5M |
Where the revenue comes from
ImmunityBio
- Product revenue, net: $50.7M (99%)
- Other revenues: $568K (1%)
Questions
Which is bigger, Monte Rosa Therapeutics or ImmunityBio?
Monte Rosa Therapeutics is the larger company: $54.4M of revenue in its latest quarter (Q3 2026) against $51.2M for ImmunityBio (Q2 2026).
Is Monte Rosa Therapeutics or ImmunityBio growing faster?
Monte Rosa Therapeutics is growing faster (+326% against +94% a year earlier).
Which is more profitable, Monte Rosa Therapeutics or ImmunityBio?
Monte Rosa Therapeutics is more profitable, with an operating margin of -3.6% against -120.4%.
More: Monte Rosa Therapeutics earnings · how Monte Rosa Therapeutics makes money · ImmunityBio earnings · how ImmunityBio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 4, 2026). Fiscal quarters can end on different dates. Not investment advice.